Pharmacogenetics of Antipsychotics: Recent Progress and Methodological Issues

Overview

Journal Expert Opin Drug Metab Toxicol

Publisher Informa Healthcare

Specialties Endocrinology
Pharmacology
Toxicology

Date 2012 Dec 4

PMID 23199282

Citations 22

Authors

Jian-Ping Zhang

Anil K Malhotra

Affiliations

Soon will be listed here.

Abstract

Introduction: Antipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers.

Areas Covered: This article reviews the recent progress in pharmacogenetic research of antipsychotic drugs since 2010, focusing on two areas: antipsychotic-induced weight gain and clozapine-induced agranulocytosis. The article also provides discussion on the important methodological issues in this area of research. The specific aim of this article is to provide the reader with up-to-date evidence in pharmacogenetic research, and for them to gain familiarity to the issues and challenges facing the field.

Expert Opinion: Pharmacogenetic studies of antipsychotic drugs are promising despite many challenges. Recent advances as reviewed in this article push the field closer to routine clinical utilization of pharmacogenetic testing. Progress in genomic technology and bioinformatics, larger sample sizes, better phenotype characterization, and careful consideration of study design issues will help to elevate antipsychotic pharmacogenetics to its next level.

Citing Articles

Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.

Tang Y, Wu Y, Li X, Hao Q, Deng W, Yue W Curr Neuropharmacol. 2022; 21(2):424-436.

PMID: 36411567 PMC: 10190139. DOI: 10.2174/1570159X21666221118164612.

Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.

Elsheikh S, Muller D, Pouget J Methods Mol Biol. 2022; 2547:389-425.

PMID: 36068471 DOI: 10.1007/978-1-0716-2573-6_14.

The Potential Role of Regulatory Genes (, , and ) in Antipsychotic Treatment Response in South African Schizophrenia Patients.

OConnell K, McGregor N, Emsley R, Seedat S, Warnich L Front Genet. 2019; 10:641.

PMID: 31354789 PMC: 6635553. DOI: 10.3389/fgene.2019.00641.

The gene and its associated phenotypes: focus on CNS drug response.

Younis R, Taylor R, Beardsley P, McClay J Pharmacogenomics. 2019; 20(9):669-684.

PMID: 31250731 PMC: 6912848. DOI: 10.2217/pgs-2019-0015.

Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.

Legge S, Walters J Pharmacogenomics. 2019; 20(4):279-290.

PMID: 30767710 PMC: 6563116. DOI: 10.2217/pgs-2018-0188.

References

Malhotra A, Zhang J, Lencz T . Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry. 2011; 17(8):760-9. PMC: 3928114. DOI: 10.1038/mp.2011.146. View

Dettling M, Schaub R, Roots I, Cascorbi I . Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics. 2001; 11(2):135-41. DOI: 10.1097/00008571-200103000-00004. View

Zhang J, Malhotra A . Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2010; 7(1):9-37. PMC: 3057913. DOI: 10.1517/17425255.2011.532787. View

Julius R, Novitsky Jr M, Dubin W . Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract. 2009; 15(1):34-44. DOI: 10.1097/01.pra.0000344917.43780.77. View

Volpi S, Potkin S, Malhotra A, Licamele L, Lavedan C . Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry. 2009; 70(6):801-9. DOI: 10.4088/jcp.08m04391. View

Purcell S, Wray N, Stone J, Visscher P, ODonovan M, Sullivan P . Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009; 460(7256):748-52. PMC: 3912837. DOI: 10.1038/nature08185. View

Park Y, Chung Y, Lee S, Lee K, Kim H, Choi J . G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients. Psychiatry Investig. 2010; 6(1):39-43. PMC: 2796038. DOI: 10.4306/pi.2009.6.1.39. View

Amar A, Segman R, Shtrussberg S, Sherman L, Safirman C, Lerer B . An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol. 2001; 1(1):41-44. DOI: 10.1017/S1461145798001023. View

Simon G, Perlis R . Personalized medicine for depression: can we match patients with treatments?. Am J Psychiatry. 2010; 167(12):1445-55. PMC: 3723328. DOI: 10.1176/appi.ajp.2010.09111680. View

10.

Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R . Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 2006; 7(5):325-32. DOI: 10.1038/sj.tpj.6500423. View

11.

Muller D, Zai C, Sicard M, Remington E, Souza R, Tiwari A . Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J. 2010; 12(2):156-64. DOI: 10.1038/tpj.2010.65. View

12.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

13.

Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A . HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet. 1998; 25(1):11-3. DOI: 10.1046/j.1365-2370.1998.00091.x. View

14.

Stefansson H, Ophoff R, Steinberg S, Andreassen O, Cichon S, Rujescu D . Common variants conferring risk of schizophrenia. Nature. 2009; 460(7256):744-7. PMC: 3077530. DOI: 10.1038/nature08186. View

15.

Dettling M, Sachse C, Muller-Oerlinghausen B, Roots I, Brockmoller J, Rolfs A . Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry. 2001; 33(6):218-20. DOI: 10.1055/s-2000-8359. View

16.

Comuzzie A, Allison D . The search for human obesity genes. Science. 1998; 280(5368):1374-7. DOI: 10.1126/science.280.5368.1374. View

17.

Reynolds G, Zhang Z, Zhang X . Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002; 359(9323):2086-7. DOI: 10.1016/S0140-6736(02)08913-4. View

18.

Velligan D, Weiden P, Sajatovic M, Scott J, Carpenter D, Ross R . The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009; 70 Suppl 4:1-46. View

19.

Ellingrod V, Perry P, Ringold J, Lund B, Bever-Stille K, Fleming F . Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet. 2005; 134B(1):76-8. DOI: 10.1002/ajmg.b.20169. View

20.

Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I . Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. J Clin Psychopharmacol. 2004; 24(6):613-7. DOI: 10.1097/01.jcp.0000144891.52858.a6. View